Posted by Michael Wonder on 25 May 2021
AbbVie receives European Commission approval of Venclyxto (venetoclax) in combination with a hypomethylating agent for patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
25 May 2021 - Venclyxto (venetoclax) in combination with a hypomethylating agent is a new regimen approved by the European Commission for patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy.
AbbVie announced today that the European Commission has approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy.
The approval is valid in all 27 member states of the EU, as well as Iceland, Liechtenstein, and Norway.
